Shari Pilon-Thomas

Highly organized and hardworking professional with more than 10 years of wet lab research experience as well as over 11 years of leadership, management, and supervisory experience. Additional 18 years experience teaching with eight years as a certified instructor in various high-stress fields. Proficient in data collection and sample coordination for clinical and research trials. Excels in planning, implementing, managing, and evaluating protocols, policies, and projects. Excellent track record of effectively and efficiently communicating necessary information to required team members and presenting data and analyses to various teams, supervisors, collaborators, and sponsors. Current research focused on the role of nitric oxide dependent processes in resistance to melanoma immune-based therapies. Recent research on the impact of the SARS-CoV-2 pandemic on cancer patients and the community, in addition to vaccine efficacy in those patients. Previous immunology research on the isolation and growth of Tumor Infiltrating Lymphocytes (TIL) and Peripheral Blood Mononuclear Cells (PBMCs) with T cell selection. Previous drug discovery research on small-molecule protein degradation and compound screening. Additional previous research utilizing Caenorhabditis elegans with focuses on anthropogenic compound toxicity, Alzheimer’s-type nerve degeneration and prevention, and establishment of a Parkinson’s-like phenotypic animal model.